The Impact of the COVID-19 Pandemic in Canadians with Cardiovascular Disease



Share Article

Published on : June 02, 2022

(2)  (605)  

What has been the impact of COVID-19 on Canadians with cardiovascular disease?


Author Reviewer

Shaun Goodman, MD, MSc

Co-Director, Canadian VIGOUR Centre, University of Alberta

Associate Head, Division of Cardiology, St. Michael's Hospital 

Toronto, ON

Milan Gupta, MD, FRCPC, FCCS, CPC(HC)

Assistant Professor, Department of Medicine, University of Toronto
Medical Director, Canadian Collaborative Research Network
Brampton, ON 



The coronavirus disease 2019 (COVID-19) pandemic has impacted cardiovascular (CV) outcomes and care globally, although to date, there is limited information describing the Canadian experience. In Sweden, which has a publicly supported and widely accessible healthcare system like Canada, COVID-19 has been identified as a risk factor for the subsequent occurrence of acute myocardial infarction (MI) and ischemic stroke, particularly in the first 2 weeks post-infection. The Swedish observations are consistent with previous studies in the pre-COVID-19 era where a transient increase in the risk of MI and stroke has been observed in association with influenza, pneumonia, acute bronchitis, and other chest infections. Thus, in addition to acute CV complications of COVID-19 itself—like myocarditis, pericarditis, decompensated heart failure (HF), and pulmonary embolism—CV implications of the pandemic will likely extend beyond direct, infection-related CV damage.

In England and the United States, several studies have also described significant early decreases in CV testing (e.g., exercise stress tests, echocardiography, nuclear imaging, coronary artery calcium scoring, coronary computed tomographic angiography, percutaneous coronary intervention, coronary artery bypass graft surgery, and transcatheter aortic valve replacement), with disproportionate impacts on older, female, and non-white patients.  While in some jurisdictions it appears that these reductions were only temporary, concern remains that the public health response to the pandemic—meant to mitigate morbidity and mortality from acute COVID-19—may have the unintended consequence of increasing CV risk in much larger proportions of the general population.

We therefore undertook an observational study aimed at characterizing trends in the use of important biomarkers of atherosclerotic cardiovascular disease (ASCVD) risk—troponin and low-density lipoprotein cholesterol (LDL-C), the use of invasive cardiac procedures, and major adverse cardiovascular events (MACE) prior to and during the COVID-19 pandemic in the province of Alberta.


Impact on ASCVD Testing

We captured population-level laboratory test volumes in all adults in Alberta between the start of the pandemic in Canada (i.e., mid-March 2019) and the end of the first year of COVID-19 (i.e., December 2020). We compared 3-month time-windows of troponin and LDL-C test volumes in different COVID-19 restriction periods during 2020 and during a pre-pandemic (2019-20) timeframe.  Almost 300,000 troponin and almost 800,000 LDL-C tests were captured in total.  Testing patterns during the COVID restriction period showed marked reduction in test volumes when compared to the previous year, particularly during the initial time-window of the COVID-19 period (March-June 2020).  However, as restrictions eased in the summer months of 2020, testing volumes rebounded to pre-pandemic volumes for both tests. In the fall of 2020, coincident with another COVID-19 wave, troponin tests decreased again. Within each of the observed drops in testing utilization, slightly larger relative declines were observed in females (vs. males) and those ≥80 years of age for troponin test volumes, and among urban (vs. rural) patients, females, and those ≤65 year of age for LDL-C test volumes.

These findings raise concerns that the pandemic may have contributed to fewer individuals being diagnosed with CV disease, and less attention paid to important CV risk factors (like dyslipidemia).

Impact on Major Adverse Cardiac Events (MACE)

Which patients should I use PCSK9 inhibitors for and when?

We further examined the impact of the first year of the pandemic on the rates of emergency department visits and hospital admissions for major adverse cardiac events (MACE), including CV death, acute coronary syndromes, ischemic stroke, or coronary revascularization procedures in Alberta.  When compared to the year prior to the pandemic (i.e., March-June 2019), MACE decreased during the initial COVID-19 restriction period (March-June 2020) and also when COVID-19 restrictions were eased during June-September 2020. Most individual MACE followed similar patterns with reduced reported events/procedures during the initial restriction period with an increase towards previous rates thereafter.  The one exception was ischemic stroke, which was not notably impacted by the pandemic.

In other words, declines in MACE/invasive cardiac procedures during the COVID-19 pandemic in Alberta are suggestive of a substantial gap in patient management and healthcare-seeking behaviour that may have negative downstream implications.

Final Reflections

Some have argued that the reductions in CV diagnostic testing, invasive procedures, and numbers of hospital admissions for CV conditions might simply reflect decreases in the occurrences of CV disease.  Unfortunately, studies from the United Kingdom and Denmark have shown that these declines in hospitalization have actually been accompanied by increases in deaths from MI and HF in the community—i.e., outside of the hospital setting.  This has led some to caution that the “collateral CV damage” of COVID-19 hasn’t been fully realized, and that “only history will reveal the depth of the iceberg”.

While we will continue to examine the Alberta population database to describe longer-term outcomes, we share the concerns that there are global implications for patients at risk for, or with, CV disease related to missed or delayed diagnosis, reduced utilization or availability of CV testing, lack of proper and timely optimization of medical treatment, prevention of exacerbations, postponed or cancelled follow-ups, and interrupted referral pathways, with reduced access to primary and specialist care.  Indeed, we need to continue to identify these trends in order to try and avoid an epidemic of CV morbidity and mortality in the coming years that could dwarf the initial health effects of COVID-19.

Click the links below to read our other blogs:

What are the updates to the clinical approach to dyslipidemia?

Why are we still talking about hypertension?

The development of this blog was overseen by the Canadian Collaborative Research Network and was supported through an educational grant from Amgen Canada. 

copyright © 2024 MDLearn
Any views expressed above are the author's own and do not necessarily reflect the views of MDLearn.

Continue learning with MDRead

Published on October 10, 2023

Preparing for Fall: Insights on Respiratory Infection Prevention and COVID Vaccination Guidance


Published on May 31, 2023

Covid-19 Protection for High-Risk Populations

Covid-19 Protection for High-Risk Populations...

Published on May 22, 2023

Chronic Urticaria

Chronic Urticaria: That Unrelenting and Nagging Itch &nb...

Published on April 25, 2023

Allergic Rhinitis

The Birds and Bees and Allergies: The Forgotten Burden of...

Published on April 06, 2023

PCSK9 inhibitors: For Which Patient and When?

PCSK9 inhibitors: For Which Patient and When?...

Published on February 10, 2023

Osteoporosis Management in Primary Care – Sinking Your Teeth Into ONJ – Debunking Myths and Unde...

Sinking Your Teeth Into ONJ – Debunking Myths and Unde...

Published on January 25, 2023

Osteoporosis Management in Primary Care – Helping patients understand the risks and benefits of os...

Denosumab 101 Safety, Tolerability and Calcium Monitoring&...

Published on January 13, 2023

Osteoporosis Management in Primary Care – Identifying when to use anabolic therapies

Osteoporosis Management in Primary Care – Anabolic The...

Published on December 10, 2022

Dyslipidemia Management in Primary Care

Dyslipidemia Management in Primary Care   This blog...

Published on December 06, 2022

Dietary Supplements

What advice do I give to my patients who use dietary supplem...

Published on October 13, 2022

Shingles Vaccination Keeping Pandora’s Box Closed

What has changed in terms of Herpes Zoster guidance and why...

Published on October 13, 2022


What’s New in Insomnia Management and Treatment &ld...

Published on September 16, 2022

When Plan B is Plan A… Meningitis B Vaccination

Meningitis B vaccination - a call to action. Why should Men...

Published on May 06, 2022

Hypertension- A Salty Topic

Why are we still talking about hypertension?   &nbs...

Published on March 31, 2022

I’m ready to use natriuretic peptide testing in my patients with dyspnea to diagnose heart failure...

How to incorporate BNP testing into primary care....